Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating Nrf2

Cellular Physiology and Biochemistry

Volumn 36, Issue 1, 2015, Pages 315-324

  Wang, Fang ^a   Pu, Chunhua ^a   Zhou, Peng ^a   Wang, Peijian ^a   Liang, Dengpan ^a   Wang, Qiulin ^a   Hu, Yonghe ^b   Li, Binghu ^c   Hao, Xinzhong ^d  

^a FIRST AFFILIATED HOSPITAL   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Nephrology and Endocrinology   (China)

Author keywords

Cinnamaldehyde; Diabetes; Endothelium; NF E2 related factor 2; Oxidative stress

Indexed keywords

3 NITROTYROSINE; CATALASE; CINNAMALDEHYDE; GLUCOSE; GLUTATHIONE PEROXIDASE 1; HEME OXYGENASE 1; HYDROETHIDINE; NAD(P)H DEHYDROGENASE QUINONE 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ACROLEIN; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR RING; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; OXIDATIVE STRESS; VASCULAR ENDOTHELIUM;

CINNAMOMUM VERUM;

ACROLEIN; ANIMALS; ANTIOXIDANTS; AORTA; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NF-E2-RELATED FACTOR 2; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84929908347     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000374074     Document Type: Article

References (30)

1. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B: The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17:S3-8.
2. Omar EA, Kam A, Alqahtani A, Li KM, Razmovski-Naumovski V, Nammi S, Chan K, Roufogalis BD, Li GQ: Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr Pharm Des 2010;16:3776-3807.
3. Orasanu G, Plutzky J: The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009;53:S35-42.
4. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR; HOPE and HOPE-TOO Trial Investigators: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-1347.
5. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM: Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300:2123-2133.
6. He M, Siow RC, Sugden D, Gao L, Cheng X, Mann GE: Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis 2011;21:277-285.
7. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD: Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011;60:3055-3066.
8. Subash-Babu P, Alshatwi AA, Ignacimuthu S: Beneficial Antioxidative and Antiperoxidative Effect of Cinnamaldehyde Protect Streptozotocin-induced Pancreatic beta-Cells Damage in Wistar Rats. Biomol Ther (Seoul) 2014;22:47-54.
9. El-Bassossy HM, Fahmy A, Badawy D: Cinnamaldehyde protects from the hypertension associated with diabetes. Food Chem Toxicol 2011;49:3007-3012.
10. Yanaga A, Goto H, Nakagawa T, Hikiami H, Shibahara N, Shimada Y: Cinnamaldehyde induces endothelium-dependent and-independent vasorelaxant action on isolated rat aorta. Biol Pharm Bull 2006;29:2415-2418.
11. Huang TC, Chung YL, Wu ML, Chuang SM: Cinnamaldehyde enhances Nrf2 nuclear translocation to upregulate phase II detoxifying enzyme expression in HepG2 cells. J Agric Food Chem 2011;59:5164-5171.
12. Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y, Sun Z, Zhang DD: Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. Free Radic Biol Med 2008;45:385-395.
13. Sun J, Pu Y, Wang P, Chen S, Zhao Y, Liu C, Shang Q, Zhu Z, Liu D: TRPVl-mediated UCP2 upregulation ameliorates hyperglycemia-induced endothelial dysfunction. Cardiovasc Diabetol2013;12:69.
14. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y: Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 2012;110:1211-1216.
15. Wang P, Yan Z, Zhong J, Chen J, Ni Y, Li L, Ma L, Zhao Z, Liu D, Zhu Z: Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. Diabetes 2012;61:2155-2165.
16. Munzel T, Heitzer T, Harrison DG: The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997;22:158-172.
17. Sasaki S, Inoguchi T: The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J 2012;36:255-261.
18. Youn HS, Lee JK, Choi YJ, Saitoh SI, Miyake K, Hwang DH, Lee JY: Cinnamaldehyde suppresses toll-like receptor 4 activation mediated through the inhibition of receptor oligomerization. Biochem Pharmacol 2008;75:494-502.
19. Subash Babu P, Prabuseenivasan S, Ignacimuthu S: Cinnamaldehyde-A potential antidiabetic agent. Phytomedicine 2007;14:15-22.
20. Zhang Y, Cao W, Xie YH, Yang Q, Li XQ, Liu XX, Wang SW: The comparison of alpha-bromo-4-chlorocinnamaldehyde and cinnamaldehyde on coxsackie virus B3-induced myocarditis and their mechanisms. Int Immunopharmacol 2012;14:107-113.
21. Hare JM, Stamler JS: NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005;115:509-517.
22. Wondrak GT, Villeneuve NF, Lamore SD, Bause AS, Jiang T, Zhang DD: The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells. Molecules 2010;15:3338-3355.
23. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270.
24. Maksimenko AV, Vavaev AV: Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart Int 2012;7:e3.
25. Howden R: Nrf2 and cardiovascular defense. Oxid Med Cell Longev 2013:104308.
26. Chauveau C, Remy S, Royer PJ, Hill M, Tanguy-Royer S, Hubert FX, Tesson L, Brion R, Beriou G, Gregoire M, Josien R, Cuturi MC, Anegon I: Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005;106:1694-1702.
27. Liu X, Wei J, Peng DH, Layne MD, Yet SF: Absence of heme oxygenase-1 exacerbates myocardial ischemia/ reperfusion injury in diabetic mice. Diabetes 2005;54:778-784.
28. Abraham NG, Kushida T, McClung J, Weiss M, Quan S, Lafaro R, Darzynkiewicz Z, Wolin M: Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circ Res 2003;93:507-514.
29. Peterson SJ, Frishman WH, Abraham NG: Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 2009;17:99-111.
30. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D: NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004;65:1238-1247